Novel Contrast Agent for MRA Approved in 34th Country

July 10, 2008 - A novel blood pool magnetic resonance angiography (MRA) agent, Vasovist (gadofosveset trisodium), has been approved for marketing in South Korea, representing the 34th country in which the agent has been approved, reported the manufacturer EPIX Pharmaceuticals Inc.

"We are pleased to announce the approval of Vasovist in South Korea, which is the 34th country outside the United States where this agent has been approved for marketing," said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. "We remain hopeful for approval of Vasovist in the United States by the end of 2008 and, as previously announced, recently resubmitted a new drug application for Vasovist to the U.S. Food and Drug Administration."

For more information: www.epixpharma.com